Latest Wellnex Life (ASX:WNX) News

Wellnex Life reports encouraging early results from its turnaround strategy, posting a modest EBITDA profit and robust sales growth for its Pain Away brand.

Wellnex Life Limited announces the resignation of CEO Zack Bozinovski, who will remain with the company until April 2026, while a $2.3 million loan repayment schedule is negotiated.

Wellnex Life reported an 18.2% sales decline in Q1 FY26 amid delayed IP licensing revenue and increased costs, while securing new debt facilities and exiting the medicinal cannabis segment.

Wellnex Life Limited reported a robust 40.5% revenue increase in FY25, driven by the full-year integration of Pain Away, while margin recovery gains momentum in the second half.

Wellnex Life Limited reported a robust 40.5% revenue increase in FY25, driven by the full-year integration of Pain Away, while margin recovery gains momentum in the second half.

Wellnex Life has secured a significant opening order from global partner Haleon for its Liquid Paracetamol and Ibuprofen softgel products in the UAE, marking the fourth national market in Haleon's distribution network. This milestone supports Wellnex's revenue forecasts for 2025 and underscores its strategic focus on innovative healthcare products.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

Wellnex Life reported a strong 40.4% revenue increase to $23.6 million in FY25, alongside a 57% improvement in normalised EBITDA loss, signaling progress despite ongoing investment costs.

Wellnex Life Limited reported a strong 40% revenue increase in FY25 driven by its Pain Away brand, yet posted a wider loss due to one-off costs and finance expenses. The company’s balance sheet strengthened following a dual AIM listing and debt settlements.

Wellnex Life announces the resignation of joint CEO George Karafotias, with Zack Bozinovski stepping up as sole CEO. The company plans to repay a $705,000 director loan within 90 days.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.